Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LAMA5 antisense RNA 1 (LAMA5-AS1)
- Target
- LAMA5-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Non-coding RNA, Other (regulatory nucleic acid molecule)
01
Overview
LAMA5 antisense RNA 1 (LAMA5-AS1) is a long non-coding RNA arising from antisense transcription of the LAMA5 gene and is distributed in both the cytoplasm and nucleus[2]. It regulates gene expression through direct interactions with key protein regulators such as NRF2 and KEAP1, influencing oxidative stress responses, cancer cell proliferation, and multidrug resistance[2]. Elevated or reduced expression of LAMA5-AS1 has been implicated in the progression of several cancers—including osteosarcoma, prostate cancer, and non-small cell lung cancer—where it functions as both a therapeutic target and a prognostic biomarker[2]. Therapeutic modulation of LAMA5-AS1 affects NRF2 and downstream genes, with potential for use in patient selection or monitoring response to cancer therapies[2].
- Other names
- LAMA5-AS1LAMA5 antisense RNA 1
02
Mechanism of action
Modulation of NRF2 transcriptional and post-translational activity, affecting cellular response to oxidative stress and chemotherapy Enhancement or repression of NRF2/KEAP1 interaction
03
Biological functions
Regulation of gene expression (at transcriptional and post-transcriptional levels)Regulates oxidative stress (via NRF2/KEAP1 interaction)Modulates multidrug resistance in cancerInhibits cell proliferation in osteosarcoma
04
Disease associations
Cancer (demonstrated roles in osteosarcoma, prostate cancer, non-small cell lung cancer)Drug resistance in cancer therapies
05
Safety considerations
Potential challenges in targeting lncRNAs therapeutically include specificity, off-target effects, and delivery to tissuesThere are no current adverse drug safety concerns reported for this molecule due to its non-coding nature and absence of specific drugs
06
Interacting drugs
Chemotherapy agents such as etoposide (VP-16), cisplatin (DDP), and carboplatin (CBP) influence LAMA5-AS1 expression and function, but there are no known direct drug molecules that target LAMA5-AS1
07
Biomarkers
LAMA5-AS1 expression level is proposed as a biomarker for cancer risk, prognosis, and drug sensitivity/resistance, especially in prostate cancer, non-small cell lung cancer, and osteosarcoma
Beyond the preview
Go deeper on LAMA5 antisense RNA 1 (LAMA5-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LAMA5 antisense RNA 1 (LAMA5-AS1).